drugset
drugset / Trial / NCT03194646

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03194646 ↗

Phase 3 Terminated 1272 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

Timeline

Start
2017-06-30
Primary completion
2019-05-10
Completion
2024-07-11

Outcome

Outcome not reported

Stopped: “Due to a change in the development program, the study was closed prematurely.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 2 mg —

Indications

uterine benign neoplasm